2 years ago
SAGE
AnalystsRitu BaralRitu Baral's Stock Forecasts
AnalystsRitu Baral
Analyst Ranking
Bottom 34%
#3406 out of 5092 analysts
Average Return
-0.01%
Win Rate
36%12 out of 33
Risk vs Reward
Poor
Good
Ritu Baral's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Palvella Therapeutics IncPVLA | +420.60% | $14.76 | $76.84 | 2025-02-04 - 2025-11-03 | Strong Buy |
Alnylam Pharmaceuticals IncALNY | +68.22% | $292.01 | $491.22 | 2024-10-20 - 2025-10-20 | Strong Buy |
Acadia Pharmaceuticals IncACAD | +61.25% | $16.62 | $26.80 | 2022-08-07 - 2023-08-07 | Buy |
Insmed IncINSM | +48.08% | $73.98 | $109.55 | 2024-08-08 - 2025-08-08 | Strong Buy |
Insmed IncINSM | +35.86% | $18.46 | $25.08 | 2022-10-20 - 2023-10-20 | Buy |
Ritu Baral Analyst Color
Get additional color on Ritu Baral's coverage of popular stocks
Ritu Baral's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Avidity Biosciences IncRNA | 2 | Hold | $74.00 | +6.02% | Downgrades | 6 days ago |
Insmed IncINSM | 4 | Strong Buy | $193.00 | +3.64% | Maintains | a month ago |
Acadia Pharmaceuticals IncACAD | 2 | Strong Buy | $39.00 | +74.34% | Maintains | 2 months ago |
Madrigal Pharmaceuticals IncMDGL | 2 | Strong Buy | $554.00 | +34.35% | Maintains | 2 months ago |
Akero Therapeutics IncAKRO | 1 | Strong Buy | $76.00 | +40.51% | Initiates Coverage On | 3 months ago |
Palvella Therapeutics IncPVLA | 1 | Strong Buy | $44.00 | -42.74% | Initiates Coverage On | 9 months ago |
Sage Therapeutics IncSAGE | 6 | Hold | $9.00 | +3.69% | Maintains | a year ago |
Alnylam Pharmaceuticals IncALNY | 3 | Strong Buy | $371.00 | N/A | Maintains | a year ago |
Ngm Biopharmaceuticals IncNGM | 2 | Hold | $1.55 | N/A | Downgrades | 2 years ago |
Sarepta Therapeutics IncSRPT | 1 | Buy | $175.00 | N/A | Maintains | 3 years ago |
Albireo Pharma IncALBO | 2 | Hold | $48.00 | N/A | Downgrades | 3 years ago |
Aptinyx IncAPTX | 1 | Hold | N/A | N/A | Downgrades | 3 years ago |
Global Blood Therapeutics IncGBT | 2 | Hold | $68.50 | N/A | Downgrades | 3 years ago |
Spero Therapeutics IncSPRO | 2 | Hold | N/A | N/A | Downgrades | 4 years ago |
An2 Therapeutics IncANTX | 1 | Buy | N/A | N/A | Initiates Coverage On | 4 years ago |
Spruce Biosciences IncSPRB | 1 | Hold | N/A | N/A | Downgrades | 4 years ago |
Rallybio CorpRLYB | 1 | Buy | N/A | N/A | Initiates Coverage On | 4 years ago |
Gh Research PLCGHRS | 1 | Buy | N/A | N/A | Initiates Coverage On | 4 years ago |
Atai Life Sciences NvATAI | 2 | Buy | N/A | N/A | Initiates Coverage On | 4 years ago |
Vera Therapeutics IncVERA | 1 | Buy | N/A | N/A | Initiates Coverage On | 4 years ago |
Terns Pharmaceuticals IncTERN | 1 | Buy | N/A | N/A | Initiates Coverage On | 5 years ago |
Myokardia IncMYOK | 1 | Hold | $225.00 | N/A | Downgrades | 5 years ago |
Intercept Pharmaceuticals IncICPT | 1 | Hold | $47.00 | N/A | Downgrades | 5 years ago |
Pliant Therapeutics IncPLRX | 1 | Buy | N/A | N/A | Initiates Coverage On | 5 years ago |
Orchard Therapeutics PLCORTX | 1 | Buy | $270.00 | N/A | Initiates Coverage On | 7 years ago |
Axon Enterprise IncAXON | 1 | Hold | N/A | N/A | Downgrades | 8 years ago |
Allena Pharmaceuticals IncALNAQ | 1 | Buy | N/A | N/A | Initiates Coverage On | 8 years ago |
Trean Insurance Group IncTIG | 1 | Buy | N/A | N/A | Initiates Coverage On | 9 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.